

Amendments to the Claims

What is claimed is:

1. to 5. (canceled).
6. (Previously amended) An isolated nucleic acid comprising a polynucleotide sequence as depicted in SEQ ID NO: 1, or of a complementary polynucleotide sequence of said isolated nucleic acid.
7. (canceled).
8. (Currently amended) The isolated nucleic acid according to claim 6, wherein the nucleic acid comprises a marker compound.
9. (Currently amended) A nucleotide probe or primer specific for an ngn3 nucleic acid, wherein the nucleotide probe or primer comprises SEQ ID NO: 1, or of a complementary polynucleotide sequence of SEQ ID NO: 1 ~~said isolated nucleic acid~~, wherein the nucleotide probe or primer comprises a marker compound.
10. to 20. (canceled).
21. (Original) A recombinant vector comprising the nucleic acid according to claim 6.
22. (Original) The recombinant vector according to claim 21, wherein the recombinant vector is an adenovirus.
23. (canceled).
24. (Original) A recombinant host cell comprising the nucleic acid according to claim 6.
25. (canceled).

26. (Original) A recombinant host cell comprising the recombinant vector according to claim 21.
27. (Original) An isolated nucleic acid encoding a polypeptide comprising an amino acid sequence of SEQ ID NO: 10.
28. (Original) A recombinant vector comprising the nucleic acid according to claim 27.
29. (Original) A recombinant host cell comprising the recombinant vector according to claim 28.
30. (Original) A recombinant host cell comprising the nucleic acid according to claim 27.
31. to 39. (canceled).
40. (Original) A pharmaceutical composition comprising the nucleic acid according to claim 6 and a physiologically compatible excipient.
41. (canceled).
42. (Original) A pharmaceutical composition comprising the recombinant vector according to claim 21 and a physiologically compatible excipient.
43. (Original) A pharmaceutical composition comprising the nucleic acid according to claim 27 and a physiologically compatible excipient.
44. (Original) A pharmaceutical composition comprising the recombinant vector according to claim 28 and a physiologically compatible excipient.

45. (Original) A pharmaceutical composition comprising the recombinant host cell according to claim 29 and a physiologically compatible excipient.

46. (Original) A pharmaceutical composition comprising the recombinant host cell according to claim 30 and a physiologically compatible excipient.

47. to 66. (canceled).